CSIMarket
 


Invitae Corporation  (NVTA)
Other Ticker:  
 
    Sector  Healthcare    Industry Medical Laboratories
   Industry Medical Laboratories
   Sector  Healthcare
 

NVTA's Revenue Growth by Quarter and Year

Invitae's Revenue results by quarter and year




NVTA Revenue (in millions $) FY 2023 FY 2022 FY 2021 FY 2020
IV Quarter December - 122.45 126.12 100.43
III Quarter September 121.24 133.54 114.40 68.73
II Quarter June 120.53 136.62 116.31 46.19
I Quarter March 117.36 123.69 103.62 64.25
FY   359.13 516.30 460.45 279.60



NVTA Revenue third quarter 2023 Y/Y Growth Comment
Invitae Corporation reported decrease in Revenue in the third quarter 2023 by -9.21% to $ 121.24 millions, from the same quarter in 2022.
The decrease in the third quarter 2023 Invitae Corporation's Revenue compares unfavorably to the Company's average Revenue jump of 79.98%.

Looking into third quarter 2023 results within Medical Laboratories industry 12 other companies have achieved higher Revenue growth. While Invitae Corporation' s Revenue decline of -9.21% ranks overall at the positon no. 1203 in the third quarter 2023.




NVTA Revenue ( Y/Y Growth %) 2023
2022 2021 2020
IV Quarter December - -2.91 % 25.58 % 51.5 %
III Quarter September -9.21 % 16.73 % 66.45 % 21.62 %
II Quarter June -11.78 % 17.46 % 151.81 % -13.63 %
I Quarter March -5.12 % 19.37 % 61.28 % 58.45 %
FY   - 12.13 % 64.68 % 28.95 %

Financial Statements
Invitae's third quarter 2023 Revenue $ 121.24 millions NVTA's Income Statement
Invitae's third quarter 2022 Revenue $ 133.54 millions Quarterly NVTA's Income Statement
New: More NVTA's historic Revenue Growth >>


NVTA Revenue (Quarter on Quarter Growth %)

2023
2022 2021 2020
IV Quarter December - -8.3 % 10.24 % 46.12 %
III Quarter September 0.59 % -2.25 % -1.64 % 48.8 %
II Quarter June 2.7 % 10.45 % 12.25 % -28.11 %
I Quarter March -4.16 % -1.93 % 3.18 % -3.08 %
FY (Year on Year)   - 12.13 % 64.68 % 28.95 %




Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #193
Overall #1203

Revenue Y/Y Growth Statistics
High Average Low
198.97 % 79.98 % -7.38 %
(Dec 31 2016)   (Sep 30 2023)
Revenue third quarter 2023 Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry #13
Healthcare Sector #193
Overall #1203
Revenue Y/Y Growth Statistics
High Average Low
198.97 % 79.98 % -7.38 %
(Dec 31 2016)   (Sep 30 2023)

Revenue by Quarter for the Fiscal Years 2020, 2021, 2022, 2023

Invitae's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
48.79 % 16.17 % -28.11 %
(Sep 30 2020)  


NVTA's III. Quarter Q/Q Revenue Comment
Invitae Corporation achieved in the III. Quarter 2023 below company average Revenue growth of 0.59% quarter on quarter, to $ 121.24 millions.

Albeit the III. Quarter 2023 NVTA's performance was lower than the average , that was still encouraging story, as the III. Quarter improvement, transcends the -2.25% growth in the III. Quarter a year ago

Within Medical Laboratories industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Invitae's Revenue growth quarter on quarter, overall rank is 1177.


Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #10
Healthcare Sector #187
Overall #1177
Revenue Q/Q Growth Company Ranking
Within: No.
Medical Laboratories Industry #10
Healthcare Sector #187
Overall #1177
Revenue Q/Q Growth Statistics
High Average Low
48.79 % 16.17 % -28.11 %
(Sep 30 2020)  


NVTA's III. Quarter Q/Q Revenue Comment
Invitae Corporation achieved in the III. Quarter 2023 below company average Revenue growth of 0.59% quarter on quarter, to $ 121.24 millions.

Although the III. Quarter 2023 NVTA's performance was beneath the average , this has been still good story, as the III. Quarter expension, eclipses the -2.25% Revenue surge in the same quarter a year ago

Within Medical Laboratories industry 9 other companies have achieved higher Revenue quarter on quarter growth. While Invitae's Revenue growth quarter on quarter, overall rank is 1177.


Invitae's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
12 Months Ending
(Sep 30 2022)
Cumulative Revenue 12 Months Ending $ 481.58 $ 493.88 $ 509.97 $ 516.30 $ 519.97
Y / Y Revenue Growth (TTM) -7.38 % -1.39 % 6.13 % 12.13 % 19.6 %
Year on Year Revenue Growth Overall Ranking # 490 # 1244 # 398 # 254 # 562
Seqeuential Revenue Change (TTM) -2.49 % -3.16 % -1.23 % -0.71 % 3.82 %
Seq. Revenue Growth (TTM) Overall Ranking # 1888 # 2779 # 2104 # 1626 # 900




Cumulative Revenue growth Comment
Invitae's cumulative 12 months Revenue continue to decline, but on the faster rate at -7.38% year on year, at Sep 30 2023 compare to the -1.39% decrease at Jun 30 2023. If the Invitae's fiscal year would end at Sep 30 2023, annual Revenue would be $482 millions.

In the Healthcare sector 123 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 490, from total ranking in previous quarter at 1244.

Revenue TTM Q/Q Growth Statistics
High Average Low
198.97 %
79.98 %
-7.38 %
 

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 19
Healthcare Sector # 124
Overall # 490

Revenue TTM Y/Y Growth Statistics
High Average Low
198.97 %
79.98 %
-7.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 320
S&P 500 # 1888
Cumulative Revenue growth Comment
Invitae's cumulative 12 months Revenue continue to decline, but on the faster rate at -7.38% year on year, at Sep 30 2023 compare to the -1.39% decrease at Jun 30 2023. If the Invitae's fiscal year would end at Sep 30 2023, annual Revenue would be $482 millions.

In the Healthcare sector 123 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 490, from total ranking in previous quarter at 1244.

Revenue TTM Q/Q Growth Statistics
High Average Low
198.97 %
79.98 %
-7.38 %
 


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Medical Laboratories Industry # 19
Healthcare Sector # 124
Overall # 490

Revenue TTM Y/Y Growth Statistics
High Average Low
198.97 %
79.98 %
-7.38 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 19
Sector # 320
S&P 500 # 1888




Other Revenue Growth
Medical Laboratories Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
NVTA's Revenue Growth Ratio versus Medical Laboratories Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth
Revenue Growth for NVTA's Competitors
Revenue Growth for Invitae's Suppliers
Revenue Growth for NVTA's Customers

You may also want to know
NVTA's Annual Growth Rates NVTA's Profitability Ratios NVTA's Asset Turnover Ratio NVTA's Dividend Growth
NVTA's Roe NVTA's Valuation Ratios NVTA's Financial Strength Ratios NVTA's Dividend Payout Ratio
NVTA's Roa NVTA's Inventory Turnover Ratio NVTA's Growth Rates NVTA's Dividend Comparisons



Companies with similar Revenue decline for the quarter ending Sep 30 2023 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2023
Procyon Corporation-0.22%$ -0.221 millions
Amedisys Inc -0.31%$ -0.314 millions
Karyopharm Therapeutics Inc -0.38%$ -0.376 millions
Establishment Labs Holdings Inc -0.50%$ -0.505 millions
Opko Health Inc -0.64%$ -0.639 millions
Integra Lifesciences Holdings Corp-0.72%$ -0.719 millions
Healthcare Services Group Inc -0.75%$ -0.748 millions
Phibro Animal Health Corporation-0.77%$ -0.772 millions
Bellicum Pharmaceuticals Inc -0.89%$ -0.890 millions
Prestige Consumer Healthcare Inc -1.12%$ -1.125 millions
Sharecare Inc -1.13%$ -1.127 millions
Lifevantage Corp-1.14%$ -1.140 millions
Organon and Co -1.17%$ -1.171 millions
Optinose Inc -1.27%$ -1.270 millions
Baxter International Inc -1.72%$ -1.723 millions
Puma Biotechnology Inc -1.73%$ -1.727 millions
Blueprint Medicines Corporation-1.76%$ -1.763 millions
Standard Biotools Inc -1.92%$ -1.918 millions
Pacira Biosciences inc -2.11%$ -2.114 millions
Bristol myers Squibb Company-2.25%$ -2.246 millions
Aurinia Pharmaceuticals Inc -2.27%$ -2.266 millions
Abbott Laboratories-2.56%$ -2.565 millions
Enhabit Inc -2.79%$ -2.785 millions
Novocure Limited-2.81%$ -2.807 millions
Uniqure N v -2.90%$ -2.899 millions
Vaso Corporation-2.92%$ -2.925 millions
Scientific Industries Inc -3.16%$ -3.165 millions
Akumin Inc -3.21%$ -3.205 millions
Syros Pharmaceuticals Inc -3.32%$ -3.315 millions
Viatris Inc -3.34%$ -3.342 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com